Connor, Clark & Lunn Investment Management (CC&L)
GYRE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Gyre Therapeutics GYRE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,055
Closed -$287K – 1024
2020
Q4 		$287K Buy
6,055
+186
+3% +$8.05K ﹤0.01% 792
2020
Q3 		$189K Sell
5,869
-2,382
-29% -$93.2K ﹤0.01% 840
2020
Q2 		$363K Sell
8,251
-281
-3% -$13.2K ﹤0.01% 809
2020
Q1 		$280K Buy
+8,532
New +$392K ﹤0.01% 812
2016
Q1 		– Sell
-131
Closed -$46K – 862
2015
Q4 		$46K Hold
131
– – ﹤0.01% 791
2015
Q3 		$68K Sell
131
-2
-2% -$3.05K ﹤0.01% 680
2015
Q2 		$291K Hold
133
– – ﹤0.01% 501
2015
Q1 		$310K Hold
133
– – ﹤0.01% 455
2014
Q4 		$275K Buy
133
+13
+11% +$25K ﹤0.01% 475
2014
Q3 		$240K Buy
120
+91
+314% +$225K ﹤0.01% 470
2014
Q2 		$109K Sell
29
-59
-67% -$193K ﹤0.01% 509
2014
Q1 		$362K Buy
+88
New +$326K ﹤0.01% 540

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GYRE Position: Q1 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Gyre Therapeutics (GYRE) in Q1 2021, closing a stake of 6,055 shares — an estimated $287K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GYRE in Q1 2014 and held it in 12 quarters. The position peaked at $363K in Q2 2020. 89 funds tracked by Wall St. Rank hold GYRE as of Q1 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Gyre Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 6,055 Gyre Therapeutics shares in Q1 2021, an estimated $287K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Gyre Therapeutics in Q1 2014 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Gyre Therapeutics position peaked at $363K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2021, filed 13 May 2021.